CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA

The aim of the study was to determine efficiency of Glutoxim, aimed for correction of immune disorders. The drug was administered to the patients with chronic cerebral ischemia (CCI, Stage I and II) complicated by arterial hypertension. Increased contents of pro- and anti-inflammatory cytokines, IFN...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. A. Shulginova, A. I. Konoplya, N. A. Bystrova, V. P. Gavriliuk, A. V. Karaulov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2018
Materias:	сhronic cerebral ischemia immune disorders glutoxim cytokines complement components Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/5c43671e252d4288a5b4d1f3a21fa828
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c43671e252d4288a5b4d1f3a21fa828
record_format	dspace
spelling	oai:doaj.org-article:5c43671e252d4288a5b4d1f3a21fa8282021-11-18T08:03:47ZCORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA1563-06252313-741X10.15789/1563-0625-2018-3-401-410https://doaj.org/article/5c43671e252d4288a5b4d1f3a21fa8282018-06-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1540https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe aim of the study was to determine efficiency of Glutoxim, aimed for correction of immune disorders. The drug was administered to the patients with chronic cerebral ischemia (CCI, Stage I and II) complicated by arterial hypertension. Increased contents of pro- and anti-inflammatory cytokines, IFNγ, IL- 2, G-CSF, and activation of the complement system have been revealed for these conditions, at both functional stages of the disease. The patients with stage II CCI showed elevated markers of oxygen-dependent activity in polymorphonuclear leukocytes (increased levels of spontaneous and stimulated nitroblue tetrazolium (NBT) reduction tests, phagocytic capacity and stimulation index of neutrophils). Stage I of chronic cerebral ischemia was characterized by normal values of NBT reduction tests and functional reserve of neutrophils, along with decreased stimulation index of neutrophils. Among 26 parameters of immune status, 73.1% and 80.8% of indices proved to be changed, respectively, in the patients with stage I and II CCI. 66.7% of immune indices appeared similar in magnitude and direction of changes, whereas the resting 33% are identical in orientation. Usage of Cereton and Actovegin in treatment of the stage I CCI caused normalization of 5.3% immune parameters, with partial normalization of 26.3% tests, and 68.4% of the indexes remaining unchanged or increased posttreatment. Inclusion of Glutoxim into the combined pharmacotherapy proved to be more effective since it totally normalized 52.6% of the indexes, along with partial normalization of 21.1%, while 26.3% of the indicators were not affected by the therapy. Administration of Cereton and Actovegin at the second stage of chronic brain ischemia was followed by partial normalization for 47,6% of the tests, while leaving unchanged or increased 52.4% of the indicators. Glutoxim Use fully normalize 19.0% and partially normalizes 57.1% of immune parameters.A. A. ShulginovaA. I. KonoplyaN. A. BystrovaV. P. GavriliukA. V. KaraulovSPb RAACIarticleсhronic cerebral ischemiaimmune disordersglutoximcytokinescomplement componentsImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 20, Iss 3, Pp 401-410 (2018)
institution	DOAJ
collection	DOAJ
language	RU
topic	сhronic cerebral ischemia immune disorders glutoxim cytokines complement components Immunologic diseases. Allergy RC581-607
spellingShingle	сhronic cerebral ischemia immune disorders glutoxim cytokines complement components Immunologic diseases. Allergy RC581-607 A. A. Shulginova A. I. Konoplya N. A. Bystrova V. P. Gavriliuk A. V. Karaulov CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA
description	The aim of the study was to determine efficiency of Glutoxim, aimed for correction of immune disorders. The drug was administered to the patients with chronic cerebral ischemia (CCI, Stage I and II) complicated by arterial hypertension. Increased contents of pro- and anti-inflammatory cytokines, IFNγ, IL- 2, G-CSF, and activation of the complement system have been revealed for these conditions, at both functional stages of the disease. The patients with stage II CCI showed elevated markers of oxygen-dependent activity in polymorphonuclear leukocytes (increased levels of spontaneous and stimulated nitroblue tetrazolium (NBT) reduction tests, phagocytic capacity and stimulation index of neutrophils). Stage I of chronic cerebral ischemia was characterized by normal values of NBT reduction tests and functional reserve of neutrophils, along with decreased stimulation index of neutrophils. Among 26 parameters of immune status, 73.1% and 80.8% of indices proved to be changed, respectively, in the patients with stage I and II CCI. 66.7% of immune indices appeared similar in magnitude and direction of changes, whereas the resting 33% are identical in orientation. Usage of Cereton and Actovegin in treatment of the stage I CCI caused normalization of 5.3% immune parameters, with partial normalization of 26.3% tests, and 68.4% of the indexes remaining unchanged or increased posttreatment. Inclusion of Glutoxim into the combined pharmacotherapy proved to be more effective since it totally normalized 52.6% of the indexes, along with partial normalization of 21.1%, while 26.3% of the indicators were not affected by the therapy. Administration of Cereton and Actovegin at the second stage of chronic brain ischemia was followed by partial normalization for 47,6% of the tests, while leaving unchanged or increased 52.4% of the indicators. Glutoxim Use fully normalize 19.0% and partially normalizes 57.1% of immune parameters.
format	article
author	A. A. Shulginova A. I. Konoplya N. A. Bystrova V. P. Gavriliuk A. V. Karaulov
author_facet	A. A. Shulginova A. I. Konoplya N. A. Bystrova V. P. Gavriliuk A. V. Karaulov
author_sort	A. A. Shulginova
title	CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA
title_short	CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA
title_full	CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA
title_fullStr	CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA
title_full_unstemmed	CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA
title_sort	correction of immune disturbances in chronic cerebral ischemia
publisher	SPb RAACI
publishDate	2018
url	https://doaj.org/article/5c43671e252d4288a5b4d1f3a21fa828
work_keys_str_mv	AT aashulginova correctionofimmunedisturbancesinchroniccerebralischemia AT aikonoplya correctionofimmunedisturbancesinchroniccerebralischemia AT nabystrova correctionofimmunedisturbancesinchroniccerebralischemia AT vpgavriliuk correctionofimmunedisturbancesinchroniccerebralischemia AT avkaraulov correctionofimmunedisturbancesinchroniccerebralischemia
_version_	1718422350422081536

CORRECTION OF IMMUNE DISTURBANCES IN CHRONIC CEREBRAL ISCHEMIA

Ejemplares similares